Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis
1. 系统已在2026-05-10 15:59:45对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1159/000549955
文献链接: https://karger.com/article/doi/10.1159/000549955
其他信息:
出版社: S. Karger AG
作者: Stephen Lam Chan; Masatoshi Kudo; Bruno Sangro; Robin Kate Kelley; Jee Hyun Kim; Binh Pham; Jung Yong Hong; Dirk-Thomas Waldschmidt; Donatella Marino; Jie Xin Joycelyn Lee; René Gerolami; Adam M. Burgoyne; Qiao Li; Hitomi Nakamura; Peng Sun; Boris Baur; Lorenza Rimassa

